World Health Organization

American College of Medical Genetics and Genomics Includes OGM in Latest Edition of Technical Laboratory Standards for Solid Tumor Analysis

Retrieved on: 
Thursday, February 22, 2024
SAN, Doctor of Philosophy, SVS, FACMG, Documentation, World Health Organization, American College, Organization, ACMG, National Comprehensive Cancer Network, OGM, Medical genetics, Publication, WHO, Cancer, Medical imaging

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in the American College of Medical Genetics and Genomics (ACMG) technical laboratory standards documentation for solid tumor analysis.

Key Points: 
  • SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in the American College of Medical Genetics and Genomics (ACMG) technical laboratory standards documentation for solid tumor analysis.
  • The technical laboratory standards were developed by a working group of laboratory geneticists performing cytogenetic studies.
  • “We are thrilled to see OGM included in the newest section of the ACMG technical laboratory standards for solid tumor studies, which provides a standardized guide for laboratory geneticists who are conducting this cytogenomic analysis.
  • We believe that cytogenomic analysis of solid tumor samples is critically important for clinical research,” added Erik Holmlin, PhD, president and chief executive officer of Bionano.

Sharps Technology Enters Latin American Market and Receives First Orders for Securegard Disposable Smart Safety Syringes from Strategic Distribution Partner in Colombia

Retrieved on: 
Wednesday, February 21, 2024
Safety, Hospital, Pharmacotherapy, World Health Organization, Sale, Pharmacy, Patient, Pharmaceutical industry

The initial product orders have been placed through a collaborative effort between Sharps and a Latin American distribution partner based in Colombia and represent a significant step towards promoting safer healthcare practices in the region.

Key Points: 
  • The initial product orders have been placed through a collaborative effort between Sharps and a Latin American distribution partner based in Colombia and represent a significant step towards promoting safer healthcare practices in the region.
  • “We are building strategic partnerships within the entire Latin American distribution network to support region-wide efforts to improve medical safety and healthcare outcomes.
  • The introduction of Securegard technology into Latin America can greatly enhance the overall quality level of healthcare available in that market.
  • For additional information on Sharps Technology and its Securegard smart safety syringes, please visit www.sharpstechnology.com .

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

Retrieved on: 
Thursday, March 7, 2024
Research, Medical Devices, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Liver, International, Neoplasm, Immunotherapy, Hepatocellular carcinoma, USAN, INN, Organization, World Health Organization, Tumor microenvironment, Patient, HCPCS, Cholangiocarcinoma, Publication, WHO, Cancer, Liver disease, Uveal melanoma

“The WHO INN and USAN approval of nelitolimod is an important milestone in the continued progress we are making with our nelitolimod program,” said Mary Szela, Chief Executive Officer and President of TriSalus.

Key Points: 
  • “The WHO INN and USAN approval of nelitolimod is an important milestone in the continued progress we are making with our nelitolimod program,” said Mary Szela, Chief Executive Officer and President of TriSalus.
  • This approach has the potential to enable more durable responses by patients to other immunotherapeutics, thereby facilitating better patient outcomes.
  • Information on nelitolimod will be posted on the USAN website ( www.ama-assn.org/go/usan ) and will be published in the Chemical Abstracts Service and in the U.S. Pharmacopeia.
  • Going forward, TriSalus will use the name in publications and public statements, at conferences and other forums, and in corporate-related materials.

HR Solution Remofirst Raises $25 Million Series A Funding to Make it Affordable and Easy to Employ Global Remote Teams

Retrieved on: 
Wednesday, March 6, 2024
Software, Technology, Professional Services, Human Resources, QED, Octopus Group, Multimedia, Volodymyr, Mastercard, World Health Organization, Organization, Tax, Zocdoc, Organizational founder, Cryptocurrency

View the full release here: https://www.businesswire.com/news/home/20240306357812/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240306357812/en/
    Remofirst cofounders Nurasyl Serik (left) and Volodymyr Fedoriv, who saw a need for a simple and affordable way for companies to legally and compliantly employ global teams, today announced $25 million in Series A venture capital funding.
  • This additional funding is a huge milestone for Remofirst, validating its vision for the future of global distributed teams and our superior solution that is affordable and easy to use.
  • The Remofirst solution leverages local in-country legal experts to ensure that its contracts are compliant in all locations, avoiding misclassification risks.
  • Prior to its Series A round, Remofirst raised $14.1 million in Seed funding in 2022.

AHF Urges WHO: Save Critical HIV Tech

Retrieved on: 
Monday, March 4, 2024
Research, General Health, Medical Devices, Healthcare Reform, Infectious Diseases, Public Policy, Advocacy Group Opinion, Health Technology, Science, Biotechnology, AIDS, Health, Government, CD4, AIDS Healthcare Foundation, POC, AHF, BD (company), World Health Organization, Abbott Laboratories, Patient, Diagnosis, WHO, HIV, Viral load, Wind, Immune system

AIDS Healthcare Foundation (AHF) urges the World Health Organization (WHO) to call on manufacturers of vital point-of-care (POC) CD4 equipment, including Abbott Laboratories and Becton Dickinson (BD), to continue production of the HIV testing equipment and any necessary commodities that ensure proper functioning.

Key Points: 
  • AIDS Healthcare Foundation (AHF) urges the World Health Organization (WHO) to call on manufacturers of vital point-of-care (POC) CD4 equipment, including Abbott Laboratories and Becton Dickinson (BD), to continue production of the HIV testing equipment and any necessary commodities that ensure proper functioning.
  • “Working in 46 countries, AHF country teams are seeing the consequences of Abbott’s and BD’s decisions firsthand, particularly in Africa and Asia.
  • CD4 testing shows how HIV damages our immune system since the virus targets and destroys CD4 cells.
  • While CD4 count is not vital for HIV diagnosis, it’s extremely important upon diagnosis, as the patient’s condition may have already progressed to AIDS—thus essential to the HIV continuum of care.

FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio

Retrieved on: 
Friday, March 1, 2024
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Therapy, Foresite Capital, GV, Artificial intelligence, Colorectal cancer, Record, Cancer, Growth, Johnson & Johnson, Helicon, MBA, Symbiosis, Data science, World Health Organization, Patient, MPH, Oncology, ARCH Venture Partners, Farallon Capital, Pharmaceutical industry

Alexis Borisy, an accomplished investor and entrepreneur, also joined the company's board of directors in the position designated to Nextech.

Key Points: 
  • Alexis Borisy, an accomplished investor and entrepreneur, also joined the company's board of directors in the position designated to Nextech.
  • The financing will fund the ongoing clinical development of FOG-001, the company’s first-in-class intracellular TCF-blocking β-catenin inhibitor currently being evaluated in a Phase 1/2 study in solid tumors.
  • The round will also accelerate the development of its robust portfolio of unique discovery programs, deepen its data science capabilities and strengthen its core Helicon therapeutics platform.
  • “Millions of colorectal cancer patients have been told by their oncologists that no more can be done for them.

Drew Barrymore Announces She’s the New Brand Ambassador for Dr. Kellyann's Breakthrough Perimenopause and Menopause Formula

Retrieved on: 
Thursday, February 29, 2024
Vitamins, Supplements, Women, Other Retail, Fitness & Nutrition, Specialty, General Health, Consumer, Health, Retail, Online Retail, Metabolism, Woman, Capsule, Shame, Multimedia, Saffron, Serotonin, Hormone, Female, Dopamine, Menopause, World Health Organization, Norepinephrine, Life, Powder, Human, Family, Insulin, MS-10, Hot, Beauty

Barrymore has been struggling with perimenopause symptoms for more than a year now, and says this product has changed her life.

Key Points: 
  • Barrymore has been struggling with perimenopause symptoms for more than a year now, and says this product has changed her life.
  • The influential voice of Drew Barrymore is helping more women than ever to feel comfortable and empowered to take control of their hormones, in a safe and natural way during perimenopause and menopause.
  • Dr. Kellyann and Drew Barrymore teamed up after Drew tried Dr. Kellyann &ME Peri + Menopause for 3 months and had incredible results.
  • To learn more about Dr. Kellyann &ME Peri + Menopause visit drkellyann.com or join the menopause conversation by following @drkellyannpetrucci across social.

Global Disinfection Robots Market Outlook & Forecast 2023-2028: The Role of AI & Robotics in Transforming Healthcare - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024
Other Science, Pharmaceutical, Research, Artificial Intelligence, Medical Devices, Infectious Diseases, Hardware, Building Systems, Hospitals, Science, Technology, Construction & Property, Clinical Trials, Medical Supplies, Biotechnology, Robotics, Health, Health Technology, Disinfectant, Incidence, Hospital, AGV, Investment, Transport, COVID-19, World Health Organization, Patient, EPA, Workforce, WHO, Workflow, Sewage treatment

The "Global Disinfection Robots Market - Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Disinfection Robots Market - Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global disinfection robot market is expected to grow from $0.28 Billion in 2022 to reach $1.42 Billion in 2028, registering a CAGR of 31%.
  • For healthcare systems, automated systems are designed to handle laboratory samples, pharmacy medicines, bulk material, central supply, and transportation.
  • The aggressive adoption of disinfection robots has increased demand and new large-scale investments worldwide, propelling the market.

Spinal Non-Fusion Devices Market Poised for Growth: Global Insights and Forecast to 2030 - Escalating Prevalence of Spinal Disorders, Advanced Product Options, and Product Developments - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, General Health, Surgery, Medical Devices, Health, Spine, Incidence, Competitive landscape, USD, FDA, Ageing, Growth, World Health Organization, Projection, Prevalence, Tetraplegia, Medtronic, NuVasive, Accident, Research, Medical device

The "Spinal Non-Fusion Devices Market Insights, Competitive Landscape and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spinal Non-Fusion Devices Market Insights, Competitive Landscape and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • According to a detailed market assessment, the Spinal Non-Fusion Devices sector was valued at a commendable USD 2,757.17 million in the year 2023.
  • The expected growth trajectory is attributed to the escalating prevalence of spinal disorders, advanced product options, and burgeoning product development endeavors.
  • With specialized segmentation ranging from product type to global geography, this comprehensive market assessment elucidates the dynamic environment of the Spinal Non-Fusion Devices market.

Radisys Unveils Engage Clarity to Enhance Phone Conversations for People Experiencing Hearing Loss

Retrieved on: 
Monday, February 26, 2024
Consumer Electronics, Technology, Health, General Health, Telecommunications, Apps, Applications, Software, Networks, Audio, Video, VoIP, Mobile, Wireless, Friends, Quality of life, Mobile World Congress, Grandparent, World Health Organization, Communication, Risk, Hearing loss, Patient, Dementia, Coffee, Lip, Monolithic kernel, OTT

Hearing difficulties are particularly challenging in phone conversations as telephony is not designed to cater to those with hearing loss, and visual cues like lip reading that can help overcome some hearing difficulties are absent.

Key Points: 
  • Hearing difficulties are particularly challenging in phone conversations as telephony is not designed to cater to those with hearing loss, and visual cues like lip reading that can help overcome some hearing difficulties are absent.
  • Radisys® Corporation , a global leader of open telecom solutions, today announced the availability of Engage Clarity , a unique service that enhances the quality and comprehensibility of voice calls for people with hearing challenges.
  • With global leadership in media processing, Radisys is uniquely positioned to deliver the benefits of Engage Clarity through service providers.
  • Radisys’ Engage Clarity offers a unique entry point for MNOs to help people manage hearing wellness by suggesting regular check-ins with the Engage hearing profile creator when they change their handset or perhaps once a year.